Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Clear Secure Inc (YOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Clear Secure Inc — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Clear Secure Inc trades at $44.26 (market cap $4.49B). The key difference: Travere Therapeutics Inc. Common Stock and Clear Secure Inc are close in size by market cap, and Clear Secure Inc pays a 1.32% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Clear Secure Inc for 20 Days on average.
| TVTX | YOU | |
|---|---|---|
Market Cap | $4.88B | $4.49B |
Volume | 1,668,577 | 1,674,277 |
Sector | Health | Technology |
52-Week High | $67.52 | $62.36 |
52-Week Low | $26.79 | $30.47 |
Typical Hold Time | 0 Days | 20 Days |
Enterprise Value | $5.01B | $3.64B |
Dividend Yield | — | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Clear Secure (YOU) trades at $43.52, up 2.5% over the past day, with a mixed technical picture showing bearish moving averages but neutral oscillators. Fundamentally, the company reported strong Q2 2026 results with EPS of $0.49 beating estimates, revenue growth of 27% year-over-year, and robust profitability metrics including a 66.66% gross margin. Recent developments include a strategic partnership with CrowdStrike and the launch of corporate memberships.
The outlook is positive given accelerating membership growth and expanding margins, though risks include competitive pressures and reliance on airport services. Analysts are generally bullish with a consensus price target of $61.40, representing significant upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
